The Governors of the University of Calgary

Artificial intelligence (AI) shows promise in enhancing the accuracy and efficiency of endoscopic assessments in inflammatory bowel disease (IBD) clinical trials. AI technologies can improve patient recruitment, endoscopy quality, and the assessment of mucosal healing, potentially transforming IBD clinical trial paradigms. Despite its potential, challenges such as dataset bias and the need for high-quality, diverse training data remain.